Advanced diagnostic imaging, including Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET), provides direct, in vivo visualization of vector biodistribution and target engagement within nonhuman primate (NHP) models. This capability is fundamental for de-risking central nervous system (CNS) programs by confirming precise delivery to intended anatomical structures, thereby generating a more robust data package for multi-jurisdictional IND, IMPD, and other global regulatory submissions. Franklin Biolabs leverages these techniques to reduce study variability and accelerate timelines for next-generation therapies.
How does advanced imaging in NHP models support IND-enabling toxicology studies for CNS-targeted therapies?
Advanced imaging provides direct, non-invasive confirmation of vector delivery to the target anatomical region. Techniques like MRI-guided stereotactic injection verify accurate administration, while PET scans can visualize metabolic activity or receptor occupancy. This minimizes variability between subjects and provides definitive evidence of target engagement, strengthening the toxicology and biodistribution data required for regulatory submissions under GxP conditions.
What is the translational relevance of using MRI-guided delivery in preclinical NHP studies?
Utilizing MRI-guided delivery in NHP models directly mirrors the procedural precision increasingly used in clinical settings. This approach ensures that the preclinical data on vector tropism, expression, and safety is generated from a highly accurate and reproducible delivery method. This alignment between preclinical and clinical procedures reduces translational gaps and provides higher confidence in the therapeutic candidate’s profile ahead of human trials.
Can imaging data help refine the study design for next-generation therapies targeting the brain?
Yes. Imaging data offers an in-life view of vector performance that can inform decisions. For example, observing non-target tissue biodistribution via imaging can help adjust dosing strategies or administration routes in subsequent cohorts. This iterative, data-driven approach allows for the refinement of the therapeutic strategy well before committing to a final study design for pivotal GxP toxicology programs.
Evaluating next-generation therapies targeting the central nervous system requires anatomical precision that cannot be adequately confirmed through post-mortem analysis alone. Direct, in vivo visualization of vector biodistribution, target engagement, and subsequent physiological response is a requirement for building a robust data package for global regulatory bodies, including those adhering to International Council for Harmonisation (ICH) guidelines.
Advanced diagnostic imaging modalities, such as MRI and PET, are integrated into our NHP programs to provide this confirmation. These techniques offer a non-invasive window into biological activity, enabling a more accurate assessment of a therapeutic candidate’s behavior in a translationally relevant large animal model.
